Disc Medicine Earnings Call Transcripts
Fiscal Year 2026
-
Lead asset bitopertin is on track for phase III data in Q4 and potential resubmission by year-end, following a regulatory setback. Pipeline programs in myelofibrosis, IBD anemia, and polycythemia vera are advancing, with multiple data readouts expected in 2024-2025.
-
Three clinical-stage programs are advancing, with key data readouts expected by year-end. The lead EPP program targets a mid-next year launch pending phase III results and regulatory review, while strong financials and capital efficiency support ongoing development.
-
FDA issued a CRL for bitopertin, citing insufficient evidence that PP9 reduction predicts clinical benefit, delaying approval. The phase III APOLLO trial is fully enrolled, with top-line data expected in Q4 2024, and the company remains confident in its design and regulatory alignment.
-
Transitioning to a commercial-stage company, the lead program for EPP is nearing FDA approval with strong clinical data and launch readiness. Pipeline assets target large, underserved hematology markets, with pivotal trials and ex-U.S. expansion planned for 2027.
Fiscal Year 2025
-
Bitopertin's NDA for EPP is under priority review, with a potential launch by January 2026 and commercial preparations accelerating. RALLY-MF phase II interim data for DISC-0974 show strong, durable anemia responses across all patient groups, supporting broad applicability and a favorable safety profile. DISC-3405 advances in PV and sickle cell disease, with robust pipeline funding into 2029.
-
Disc Medicine is advancing three clinical programs targeting rare blood disorders, with bitopertin for EPP nearing potential FDA approval and launch, and DISC-0974 showing promising phase 2 results in myelofibrosis anemia. The company is well-funded, with $825 million to support its pipeline.
-
Multiple late-stage programs are advancing, with Bidapertin's NDA under accelerated review and potential approval by early 2024. Commercial launch preparations are underway, leveraging targeted patient identification and a staged infrastructure build. Strong financial position supports execution through key milestones.
-
Bitopertin is on an accelerated FDA review for EPP, with launch preparations focused on 6,000 engaged patients and a 24-rep sales force. Pipeline assets show strong clinical progress in anemia and polycythemia vera, while cash reserves of $826 million provide a runway through early 2029.
-
Three clinical-stage programs target red blood cell disorders, with bitopertin nearing NDA submission and a rare disease launch planned. Commercial strategy focuses on a 6,000-patient core, with pricing in the rare disease range. Strong clinical data, favorable regulatory environment, and robust cash position support growth.
-
Bitopertin is advancing toward NDA filing with strong clinical and regulatory momentum, while commercial and pediatric strategies are in place. Pipeline assets show promise in myelofibrosis, CKD anemia, and polycythemia vera, with key data readouts expected soon.
-
Bitopertin is advancing toward NDA submission for EPP, supported by strong phase II data and an accelerated approval pathway. The company targets a 14,000-patient U.S. market, with robust financial resources to support multiple late-stage programs and aims for broad commercialization and pipeline expansion.
-
Bitopertin is advancing toward NDA filing with a potential launch next year, supported by robust patient identification and a focused launch strategy. DISC-0974 is emerging as a leading therapy for anemia in myelofibrosis, with key data readouts and trial updates expected by year-end.
-
New data from three clinical programs show durable efficacy and safety, with bitopertin advancing toward NDA submission and commercial launch for EPP, DISC-0974 progressing in MF anemia with protocol expansion, and DISC-3405 initiating a phase 2 PV trial. Key regulatory milestones and market opportunities remain on track.
-
Bitopertin advances toward NDA filing for EPP with strong FDA support and robust phase 2 data, while commercial plans target a highly engaged patient base. Additional assets in anemia and PV are progressing, with the company emphasizing capital efficiency and revenue-driven growth.
-
FDA alignment achieved for accelerated approval in EPP, with NDA filing expected in H2 and confirmatory trial results anticipated by end of next year. Market opportunity targets 6,000–14,000 US patients, with robust efficacy data supporting launch. Anemia program 0974 advances in MF and CKD, aiming for broad applicability and clear regulatory paths.
-
FDA granted accelerated approval pathway for bitopertin in EPP, with strong phase II data supporting PPIX reduction as a surrogate endpoint. Commercial launch is now targeted for next year, with operational readiness and outreach strategies in place. DISC-0974 shows promise in anemia for MF and CKD, with key data readouts expected within 12–18 months.
-
Anemia in myelofibrosis remains a major unmet need, with current therapies often worsening anemia and no approved anemia-specific treatments. DISC-0974 has shown promising efficacy and safety in early trials, with broad applicability across patient segments and strong physician interest, positioning it as a potential blockbuster therapy.
-
The company is advancing a robust pipeline for hematologic disorders, with its lead program bitopertin nearing NDA filing and commercialization for EPP. Strong clinical data, a larger-than-expected market, and a solid financial position support multiple late-stage programs and anticipated growth in 2026.
-
The company is advancing three clinical-stage programs targeting rare and large anemia indications, with bitopertin leading in EPP and on track for an NDA filing in the second half of the year. Strong clinical data, clear regulatory alignment, and robust financial resources support broad development and commercialization plans.
-
The company is advancing a robust pipeline targeting red blood cell disorders, with bitopertin leading in EPP and regulatory milestones expected this year. Strong clinical data and FDA alignment support accelerated approval, while additional programs in myelofibrosis and CKD show promising efficacy and market potential.
-
Alignment with FDA enables APOLLO confirmatory trial for bitopertin in EPP, using PPIX reduction and sunlight tolerance as co-primary endpoints. Phase II data showed strong efficacy and safety, with NDA submission planned for the second half of the year and commercial readiness underway.
Fiscal Year 2024
-
Significant clinical progress was reported for three investigational agents, with bitopertin advancing toward accelerated approval in EPP, DISC-0974 showing strong efficacy in myelofibrosis anemia, and DISC-3405 demonstrating proof of mechanism for iron restriction. Expansion into additional indications and robust commercialization plans were outlined.
-
Bitopertin showed strong phase 2 results in EPP, supporting accelerated approval, with a confirmatory phase 3 trial starting by mid-2025. The commercial opportunity is significant, with a large US patient base and simple oral therapy. DISC-0974 is promising in anemia of inflammation, and the company is well funded.
-
Three clinical programs are advancing, with bitopertin showing strong phase II results in EPP and a clear path to accelerated approval. DISC-0974 demonstrates robust efficacy in myelofibrosis and CKD anemia, while financial flexibility and manufacturing partnerships support continued growth.
-
Full FDA alignment was achieved for the bitopertin EPP program, including acceptance of the primary endpoint and trial design. Strong efficacy and safety data support an accelerated approval pathway, with NDA submission planned and commercial preparations underway.
-
Three clinical programs are advancing, with Bitapertin moving toward phase III in EPP, DISC-0974 showing strong results in anemia, and DISC-3405 targeting polycythemia vera. Key data and regulatory milestones are expected in the second half of the year.
-
The company is advancing three hematology assets, with bitopertin nearing phase III for EPP and showing strong efficacy in open-label studies. Additional programs target rare anemia and myelofibrosis, with promising early data and regulatory milestones expected by year-end.
-
The company highlighted strong phase 2 results for Bitopertin in EPP, with significant improvements in light tolerance and quality of life. Plans for phase III focus on robust endpoints, and pipeline updates include promising data for DISC-0974 and DISC-3405 in anemia and polycythemia vera.
-
Three mid-stage clinical programs are advancing, led by bitopertin for EPP, which showed strong efficacy in phase II and is preparing for phase III. Additional assets target anemia in myelofibrosis and CKD, and polycythemia vera, with robust safety and promising early data. $501M in cash supports operations into 2027.
-
Phase 2 data for three investigational agents showed strong efficacy and safety, with bitopertin improving light tolerance and reducing pain in EPP, DISC-0974 increasing hemoglobin and reducing transfusion needs in myelofibrosis, and DISC-3405 achieving targeted iron reduction. Multiple pivotal trials and data readouts are planned for late 2024 and 2025.
-
Three clinical-stage programs targeting red blood cell disorders are advancing, with bitopertin showing strong efficacy in EPP and plans for pivotal trials, DISC-0974 demonstrating robust responses in myelofibrosis, and DISC-3405 progressing toward polycythemia vera. Multiple data releases are expected at EHA and throughout the year.